Add To Watchlist
Share URL
About The Company
CEO
Dr. Gregory A. Demopulos M.D.
Market Cap
210.92 Million USD
Sector
Healthcare
Website
https://www.omeros.comLast Update
2/22/2024, 12:00:00 PM
Description
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders.
Read More
Overview
Value
41
Growth
20
Health
59
Management
0
Analyst Opinion
54
Total
40
All Scores Out Of 100
Best Features
- Price-to-earnings ratio of 12.6 is lower than the market average (19.6x)
- Low preportion of income is paid as dividend
Risk Factors
- Earnings have declined recently
- Has a high level of debt
- Altman-Z score suggests a risk of bankruptcy
- Disliked by Twitter users
- Poor earnings and cashflow growth
- Dividend could be at risk
Market Peers
OMER
Key Figures
PE Ratio (TTM)
12.59
Margin Of Safety (DCF)
N/A
Revenue Growth (5 Year Average)
N/A
Ratings Consensus
Neutral
Share Buybacks
N/A
Dividend Yeild (TTM)
0.00%
Valuation
Value Score
41
Desired Margin Of Safety
0%
▼
Tip: Set your desired Margin Of Safety
Free Cash Flow Type
Annual Cashflow Growth
0%
Discount Rate
0%
Buy Target: N/A✘
Current Price: 4 USD
Negative Cashflows: Cashflow can become negative due to operating losses, investing activities or financing activites. Negative cashflow makes it dificult to use a discounted free cashflow model to assess intrinsic value.
How Does This Work?
Show Advanced Options
This calculator helps investors estimate the Intrinsic Value of a company based on the current value of future cash flows. To use the tool, simply input a desired Margin Of Safety, which is an additional discount applied to the present value of the expected future cash flows. The tool calculates the present value using a discount rate that reflects the risk and time value of money, and provides an estimated target price for the company based on the selected margin of safety. The calculator defaults to using 5 Year Free Cash Flow Growth % and a discount rate based on the US 10-year treasury bond coupon rate. Use our performance analyser to get a feel the impact this has on longterm investment returns and discover a margin of safety you are comfortable with. This can be a useful tool for investors looking to make informed decisions about whether to buy or sell shares of a particular company.
Price/Earnings
12.59x
Free Cashflow Yeild
33.10%
PE/Earnings Growth
N/A
Price/Book
-18.16x
Growth
Growth Score
20
- ✔ Revenue growth has improved this yeara
- ✔ Free Cashflow growth has improved this year
- ✘ 5 Year Average Revenue growth of N/A is lower than the market average (10.97%)
- ✘ 5 Year Average Earnings growth of N/A is lower than the market average (14.48%)
- ✘ Earnings growth has slowed this year
- ✘ 5 Year Average Free Cashflow growth of N/A is lower than the market average (12.35%)
Revenue Growth
N/A
Earnings Growth
N/A
Cashflow Growth
N/A
Health
Health Score
59
Altman Z Score
0.00
Piostroski Score
5.00
Debt/Equity
14.63x
Current Assets/Liabilities
4.79x
Free Cashflow/Total Debt
0.00x
Debt/Capital
1.40x
Dividend
Secure Dividend Score
0
- ✔ Long term dividend payout ratio of 0.00% is considered good
- ✔ Payout ratio (TTM) of 0.00% is lower than the average (40%)
- ✔ Dividends have shown growth over the last 5 years
- ✔ Spending a lower percentage of their income on dividends than last 5 years
- ✘ Dividend yeild of 0.00% is less than the market average (1.85%)
- ✘ Very unsafe
Dividend Yeild
0.00%
Dividend Growth
N/A
Payout Ratio (Earnings)
0.00%
Payout Ratio (Cashflow)
0.00%
Management
Management Score
0
Average Buybacks/Dilution
N/A
Recent Buybacks/Dilution
0.84%
5 Year Price Volitility
32.47%
Return On Assets
46.78%
Return On Capital Employed
46.00%
Return On Equity
824.81%
Return On Free Cashflow
N/A
Return On Investments
N/A
Analysts
Analyst Opinion
54
- ✔ Ratings consensus is Neutral
SEC Filings
Find yearly (10-K), quaterly (10-Q) and disclosure (8-K) report here, on the Securities and Exchange Commission's EDGAR database. If reading through reports isn't your cup of tea, don't worry. We've made it easy for you by summarizing all the important bits.
Other Information
Company Name
Omeros Corporation
Currency
USD
Beta
0.984631
Vol Avg
689108
Ceo
Dr. Gregory A. Demopulos M.D.
Cik
0001285819
Cusip
682143102
Exchange
NASDAQ Global Market
Full Time Employees
196
Industry
Biotechnology
Sector
Healthcare
Ipo Date
2009-10-08
Address
The Omeros Building
City
Seattle
State
WA
Country
US
Zip
98119
Phone
206 676 5000
Analysis Last Updated
2/22/2024, 12:00:00 PM
All financial data provided by FMP
Social Sentiment
Social Sentiment Score
26
Twitter Sentiment
0.00
Stocktwits Sentiment
51.00